Australia markets open in 1 hour 39 minutes

TC Biopharm (Holdings) Plc (TCBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.2200+0.1400 (+12.96%)
At close: 04:00PM EST
1.1700 -0.05 (-4.10%)
After hours: 04:06PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.0800
Open1.1000
Bid1.2300 x 1200
Ask1.2400 x 3200
Day's range1.0701 - 1.4204
52-week range0.8500 - 1,042.0000
Volume1,335,379
Avg. volume769,841
Market cap2.96M
Beta (5Y monthly)0.04
PE ratio (TTM)N/A
EPS (TTM)-71.4600
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est140.00
  • PR Newswire

    TCBP Announces MHRA Acceptance of Amendment for ACHIEVE UK Trial

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the MHRA has officially accepted its proposed amendment to the Company's clinical trial authorisation (CTA). The amendment allows for an increase in dosing size of TCB008 (unmodified expanded gamma delta T cell Lymphocytes) to 12x10^7-23x10^7 gamma delta t-cells.

  • PR Newswire

    TC BioPharm Management to Participate at Upcoming 7th CAR-TCR Summit Europe

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that CEO, Bryan Kobel and Process Development Manager, Dr. Lauren Bor will be featured "Expert Speakers" at the 7th 7th CAR-TCR Summit Europe, February 27-29th in London, UK.

  • PR Newswire

    TCBP Provides Shareholder Update and Highlights Upcoming Milestones

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a shareholder update with a projected outlook for the current year.